Emergent Biosolutions, Inc. (EBS) Stock Price

EBSStock

$5.91−29.56%52W

Market Cap$303.03M

P/E4.44x

PEG Ratio0.38

Div yield—

Beta2.33

EBS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-58.01%

Price vs S&P 500 (4W)-21.78%

PEG Ratio0.38

VGM Score47.20

P/E Ratio (Annual)4.44x

P/CF (Annual)1.37x

Book Value / Share (Quarterly)$10.10

P/TBV (Annual)7.54x

Revenue Growth (3Y)-12.81%

Cash Flow / Share (Quarterly)$2.61

Price vs S&P 500 (YTD)-65.01%

Gross Margin (TTM)54.26%

Net Profit Margin (TTM)-1.27%

EPS (TTM)$-0.24

10-Day Avg Trading Volume1.19M

EPS Excl Extra (TTM)$-0.24

Revenue Growth (5Y)-13.74%

EPS (Annual)$0.93

ROI (Annual)4.80%

Gross Margin (Annual)56.09%

Net Profit Margin (5Y Avg)-18.06%

Cash / Share (Quarterly)$3.09

P/E Basic Excl Extra (TTM)9.41x

Revenue Growth QoQ (YoY)-29.75%

EPS Growth (5Y)-30.38%

P/E Normalized (Annual)4.44x

ROA (Last FY)3.99%

Revenue Growth TTM (YoY)-29.89%

EBITD / Share (TTM)$2.30

ROE (5Y Avg)-29.65%

Operating Margin (TTM)8.97%

Cash Flow / Share (Annual)$3.01

P/B Ratio0.45x

P/B Ratio (Quarterly)0.82x

Net Income / Employee (Annual)$58,400

EV / Revenue (TTM)0.96x

Net Interest Coverage (TTM)2.40x

ROA (TTM)-0.62%

EPS Growth QoQ (YoY)-89.85%

EV / EBITDA (TTM)5.13x

EPS Incl Extra (Annual)$0.93

Current Ratio (Annual)5.01x

Quick Ratio (Quarterly)1.90x

3-Month Avg Trading Volume0.97M

52-Week Price Return-29.56%

EV / Free Cash Flow (Annual)4.12x

P/E Incl Extra (TTM)9.41x

Revenue / Employee (TTM)$752,000

Tangible BV / Share (Quarterly)$1.02

P/S Ratio (Annual)0.31x

Asset Turnover (Annual)0.56x

52-Week High$14.06

Operating Margin (5Y Avg)-10.91%

EPS Excl Extra (Annual)$0.93

CapEx CAGR (5Y)-38.03%

Tangible BV CAGR (5Y)-24.31%

26-Week Price Return-46.08%

Quick Ratio (Annual)2.22x

13-Week Price Return-35.62%

Total Debt / Equity (Annual)1.09x

Current Ratio (Quarterly)4.29x

Enterprise Value$646.59M

Revenue / Share Growth (5Y)-14.64%

Asset Turnover (TTM)0.49x

Book Value / Share Growth (5Y)-18.12%

Revenue / Employee (Annual)$825,400

Inventory Turnover (Annual)1.00x

Pretax Margin (Annual)11.15%

Cash / Share (Annual)$3.94

3-Month Return Std Dev80.54%

Gross Margin (5Y Avg)43.73%

Net Income / Employee (TTM)$-9,600

EBITDA CAGR (5Y)-20.88%

EBITDA Interim CAGR (5Y)-24.53%

ROE (Last FY)10.07%

Net Interest Coverage (Annual)1.06x

EPS Basic Excl Extra (Annual)$0.93

P/FCF (TTM)1.32x

Receivables Turnover (TTM)4.16x

EV / Free Cash Flow (TTM)4.78x

Total Debt / Equity (Quarterly)1.10x

EPS Incl Extra (TTM)$-0.24

Receivables Turnover (Annual)6.22x

ROI (TTM)-0.74%

P/S Ratio (TTM)0.34x

Pretax Margin (5Y Avg)-14.97%

Revenue / Share (Annual)$13.10

Tangible BV / Share (Annual)$1.65

Forward P/E16.43x

Free OCF CAGR (5Y)-16.44%

Price vs S&P 500 (52W)-48.12%

P/E Ratio (TTM)9.41x

Year-to-Date Return-52.18%

5-Day Price Return14.09%

EPS Normalized (Annual)$0.93

ROA (5Y Avg)-10.14%

Net Profit Margin (Annual)7.08%

Month-to-Date Return-18.14%

Cash Flow / Share (TTM)$-9.38

EBITD / Share (Annual)$2.70

Operating Margin (Annual)11.83%

LT Debt / Equity (Annual)1.09x

P/CF (TTM)1.58x

ROI (5Y Avg)-12.17%

P/E Excl Extra (TTM)9.41x

LT Debt / Equity (Quarterly)1.10x

EPS Basic Excl Extra (TTM)$-0.24

P/TBV (Quarterly)8.13x

P/B Ratio (Annual)1.24x

Inventory Turnover (TTM)0.97x

Pretax Margin (TTM)0.52%

Book Value / Share (Annual)$10.03

Price vs S&P 500 (13W)-37.58%

Net Margin Growth (5Y)-18.44%

Beta2.33x

P/FCF (Annual)1.49x

Revenue / Share (TTM)$11.98

ROE (TTM)-1.59%

52-Week Low$4.36

vGradeA

gGradeF

mGradeD

vgmGradeC

EBS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.11	$0.60	+445.45%(+$0.49)
Q1 2026	Apr 30, 2026	-$0.25	$0.21	+184.00%(+$0.46)
Q4 2025	Feb 26, 2026	$0.11	-$0.43	-490.91%(-$0.54)
Q3 2025	Oct 29, 2025	-$0.12	$1.06	+984.22%(+$1.18)
Q2 2025	Aug 6, 2025	-$0.49	$0.16	+132.73%(+$0.65)

EBS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
EBSEmergent Biosolutions, Inc.	A	F	D	$5.91
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Emergent Biosolutions, Inc.

Emergent BioSolutions develops and manufactures pharmaceutical products and medical countermeasures for public health markets. The company operates three main segments: commercial respiratory products including NARCAN and KLOXXADO nasal sprays; government-contracted medical countermeasures such as anthrax and smallpox vaccines; and bioservices. Revenue is primarily derived from the U.S. market.